Glucagon-like peptide-1 receptor agonist use is associated with lower serum periostin
Dinah Foer
Division of Allergy and Clinical Immunology, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA
Harvard Medical School, Boston, Massachusetts, USA
Division of General Internal Medicine and Primary Care, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA
Search for more papers by this authorPatrick E. Beeler
Harvard Medical School, Boston, Massachusetts, USA
Division of General Internal Medicine and Primary Care, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA
Division of Occupational and Environmental Medicine; Epidemiology, Biostatistics and Prevention Institute, University of Zurich and University Hospital Zurich, Zurich, Switzerland
Center for Primary and Community Care, University of Lucerne, Lucerne, Switzerland
Search for more papers by this authorJing Cui
Harvard Medical School, Boston, Massachusetts, USA
Division of Rheumatology, Inflammation and Immunity, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA
Search for more papers by this authorWilliam E. Snyder
Division of Diabetes, Endocrinology, and Metabolism, Vanderbilt University Medical Center, Nashville, Tennessee, USA
Search for more papers by this authorMona Mashayekhi
Division of Diabetes, Endocrinology, and Metabolism, Vanderbilt University Medical Center, Nashville, Tennessee, USA
Search for more papers by this authorHui Nian
Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
Search for more papers by this authorJames M. Luther
Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
Search for more papers by this authorElizabeth W. Karlson
Harvard Medical School, Boston, Massachusetts, USA
Division of Rheumatology, Inflammation and Immunity, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA
Search for more papers by this authorJoshua A. Boyce
Division of Allergy and Clinical Immunology, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA
Harvard Medical School, Boston, Massachusetts, USA
Search for more papers by this authorCorresponding Author
Katherine N. Cahill
Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA
Correspondence
Katherine N. Cahill, Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, 2525 West End Avenue, Suite 450, Nashville, TN, USA.
Email: [email protected]
Search for more papers by this authorDinah Foer
Division of Allergy and Clinical Immunology, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA
Harvard Medical School, Boston, Massachusetts, USA
Division of General Internal Medicine and Primary Care, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA
Search for more papers by this authorPatrick E. Beeler
Harvard Medical School, Boston, Massachusetts, USA
Division of General Internal Medicine and Primary Care, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA
Division of Occupational and Environmental Medicine; Epidemiology, Biostatistics and Prevention Institute, University of Zurich and University Hospital Zurich, Zurich, Switzerland
Center for Primary and Community Care, University of Lucerne, Lucerne, Switzerland
Search for more papers by this authorJing Cui
Harvard Medical School, Boston, Massachusetts, USA
Division of Rheumatology, Inflammation and Immunity, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA
Search for more papers by this authorWilliam E. Snyder
Division of Diabetes, Endocrinology, and Metabolism, Vanderbilt University Medical Center, Nashville, Tennessee, USA
Search for more papers by this authorMona Mashayekhi
Division of Diabetes, Endocrinology, and Metabolism, Vanderbilt University Medical Center, Nashville, Tennessee, USA
Search for more papers by this authorHui Nian
Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
Search for more papers by this authorJames M. Luther
Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
Search for more papers by this authorElizabeth W. Karlson
Harvard Medical School, Boston, Massachusetts, USA
Division of Rheumatology, Inflammation and Immunity, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA
Search for more papers by this authorJoshua A. Boyce
Division of Allergy and Clinical Immunology, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA
Harvard Medical School, Boston, Massachusetts, USA
Search for more papers by this authorCorresponding Author
Katherine N. Cahill
Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA
Correspondence
Katherine N. Cahill, Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, 2525 West End Avenue, Suite 450, Nashville, TN, USA.
Email: [email protected]
Search for more papers by this author[Correction added on 14 April 2023, after first online publication: the subheadings were removed throughout the research letter to adhere to journal style.]
Open Research
DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.
REFERENCES
- 1Wu AY, Cahill KN, Toki S, Peebles RS Jr. Evaluating the glucagon-like peptide-1 receptor in managing asthma. Curr Opin Allergy Clin Immunol. 2022; 22(1): 36-41. doi:10.1097/aci.0000000000000797
- 2Foer D, Beeler PE, Cui J, Karlson EW, Bates DW, Cahill KN. Asthma exacerbations in type 2 diabetics with asthma on glucagon-like peptide-1 receptor agonists. Am J Respir Crit Care Med. 2020. doi:10.1164/rccm.202004-0993OC
- 3Rogliani P, Calzetta L, Capuani B, et al. Glucagon-like peptide 1 receptor: a novel pharmacological target for treating human bronchial hyperresponsiveness. Am J Respir Cell Mol Biol. 2016; 55(6): 804-814. doi:10.1165/rcmb.2015-0311OC
- 4López-Cano C, Ciudin A, Sánchez E, et al. Liraglutide improves forced vital capacity in individuals with type 2 diabetes: data from the randomized crossover LIRALUNG study. Diabetes. 2022; 71(2): 315-320. doi:10.2337/db21-0688
- 5Hogan AE, Gaoatswe G, Lynch L, et al. Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus. Diabetologia. 2014; 57(4): 781-784. doi:10.1007/s00125-013-3145-0
- 6Izuhara K, Nunomura S, Nanri Y, Ono J, Takai M, Kawaguchi A. Periostin: an emerging biomarker for allergic diseases. Allergy. 2019; 74(11): 2116-2128. doi:10.1111/all.13814
- 7Mashayekhi M, Beckman JA, Nian H, et al. Comparative effects of weight loss and incretin-based therapies on vascular endothelial function, fibrinolysis and inflammation in individuals with obesity and prediabetes: a randomized controlled trial. Diabetes Obes Metab. 2022; 25: 570-580. doi:10.1111/dom.14903
- 8Mitchell PD, Salter BM, Oliveria JP, et al. Glucagon-like peptide-1 receptor expression on human eosinophils and its regulation of eosinophil activation. Clin Exp Allergy. 2017; 47(3): 331-338. doi:10.1111/cea.12860
- 9Altintas Dogan AD, Hilberg O, Hess S, Jensen TT, Bladbjerg EM, Juhl CB. Respiratory effects of treatment with a glucagon-like Peptide-1 receptor agonist in patients suffering from obesity and chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2022; 17: 405-414. doi:10.2147/copd.S350133
Citing Literature
